Swedish Orphan Biovitrum AB (Sobi) has decided to withdraw its New Drug Application (NDA) for an oral suspension of Orfadin in the US. The decision to withdraw the current application is based on a request for further information by the US Food and Drug Administration (FDA) regarding the usability by the intended user population of the Orfadin oral suspension and the oral syringe to be included in the package.

Sobi will discuss a re-submission date for the Orfadin oral suspension with the FDA in Q1 2014.

Orfadin is used for the treatment of hereditary Tyrosinaemia type 1 (HT-1), a rare genetic disorder which can cause liver failure, kidney dysfunction and neurological problems.

Sobi is an international specialty healthcare company dedicated to rare diseases to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within haemophilia and neonatology.